ABSTRACT
OBJECTIVE: Introduction: Gout is associated closely with an increased risk of cardiovascular (CV) events including heart failure. The aim: Improvement of treating patients with gout and essential hypertension (EH) by applying course therapy of quercetin of the echocardiographic parameters of the left ventricular diastolic function. PATIENTS AND METHODS: Materials and methods: 84 male patients with gout and EH. The main group consists of 43 patients who have performed treatment with quercetin and a comparative group of 41 patients who were performed treatment without quercetin. RESULTS: Results: In patients with gout in combination with EH, the addition of quercetin to antihypertensive and urate-lowering treatment have a protective effect on cardiac diastolic function (the baseline-adjusted changes during 12 months were significantly lower in the quercetin group than in the comparative group for E/e' (-0,41± 0,01 vs. -0,08 ± 0,01, p = 0,001) and LV mass index, g/m2 (-3,28 ± 0,02 vs. -2,04 ± 0,03, p = 0,02). Also this combination contributed to faster and more pronounced achievement of the target level of uric acid (reduction by 33,7%), normalize renal function (the rate of glomerular filtration, ml/min/1,73 m2 level increase by 13,3%) and also had a cumulative antihypertensive effect (reduction of systolic blood pressure by 5,5% and diastolic blood pressure by 3,6%) without increasing the dose or adding new antihypertensive drugs. CONCLUSION: Conclusion: adding quercetin to antihypertensive and urate-lowering regimens for 12 months in patients with gout and EH improve echocardiographic parameter of diastolic function left ventricular, purine metabolism, renal function and additional normalize blood pressure.